insulin

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
GDM: Insulin with or Without Metformin?	2025/01/17	NCT06781775	Phase 4	Recruiting	University of Virginia
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes	2025/01/07	NCT06762314	Phase 2	Recruiting	Mostafa Bahaa
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity	2024/11/21	NCT06699810	Phase 4	Recruiting	Emory University
Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus	2024/09/19	NCT06601101	Phase 3	Recruiting	University of Campinas, Brazil
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes	2024/06/06	NCT06445946	Phase 4	Recruiting	Ohio State University
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)	2024/05/17	NCT06419803	Not Applicable	Recruiting	Thomas Jefferson University
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes	2024/05/17	NCT06419777	Not Applicable	Recruiting	Thomas Jefferson University
Topical Insulin for Postoperative Wound Healing	2024/05/06	NCT06400082	Not Applicable	Active, not recruiting	Cairo University
Regional Lipolysis Insulin Regulation	2024/05/01	NCT06392854	Early Phase 1	Recruiting	Mayo Clinic
Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study	2024/04/30	NCT06391853	Not Applicable	Withdrawn	Erasme University Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
HUMULIN R insulin 100IU/mL injection vial	14635	Eli Lilly Australia Pty Ltd	Medicine	A	9/5/1991
MIXTARD 50/50 PENFILL human insulin (rys) 100IU/mL injection multidose cartridge	169630	Novo Nordisk Pharmaceuticals Pty Ltd	Medicine	A	4/28/2011
HUMULIN NPH biosynthetic human isophane insulin 100IU/mL injection multidose cartridge	39662	Eli Lilly Australia Pty Ltd	Medicine	A	5/11/1992
ACTRAPID PENFILL human insulin (rys) 100IU/mL injection multidose cartridge	169623	Novo Nordisk Pharmaceuticals Pty Ltd	Medicine	A	4/28/2011
ACTRAPID human insulin (rys) 100IU/mL injection multidose vial	169625	Novo Nordisk Pharmaceuticals Pty Ltd	Medicine	A	4/28/2011
HUMULIN 30/70 biosynthetic human 30% neutral 70% isophane insulin 100IU/mL injection 10mL vial	39656	Eli Lilly Australia Pty Ltd	Medicine	A	5/11/1992
HUMULIN 30/70 biosynthetic human 30% neutral 70% isophane insulin 100IU/mL injection multidose cartridge	39659	Eli Lilly Australia Pty Ltd	Medicine	A	5/11/1992
PROTAPHANE PENFILL human insulin (rys) 100IU/mL injection multidose cartridge	169635	Novo Nordisk Pharmaceuticals Pty Ltd	Medicine	A	4/28/2011
HUMULIN NPH human insulin 100IU/mL injection vial	14634	Eli Lilly Australia Pty Ltd	Medicine	A	9/5/1991
PROTAPHANE human insulin (rys) 100IU/mL injection multidose vial	169637	Novo Nordisk Pharmaceuticals Pty Ltd	Medicine	A	4/28/2011

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
LENTE PURIFIED PORK INSULIN INJ	ELI LILLY AND COMPANY LIMITED	00514535	Suspension (Lente) - Subcutaneous	100 UNIT / ML	12/31/1980
HUMULIN 30/70 (INSULIN HUMAN BIOSYNTH INJ)	eli lilly canada inc	00795879	Suspension - Subcutaneous	30 UNIT / ML	12/31/1989
MTB-TOX	bio active canada ltd.	02233653	Liquid - Oral	6 X	5/26/1998

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Skin-Permeable Polymer Delivers Insulin Through Topical Cream, Offering Needle-Free Diabetes Treatment

4 days ago

Researchers at Zhejiang University developed a skin-permeable polymer that successfully delivers insulin through the skin, potentially eliminating the need for injections in diabetes management.

Pluristyx Secures $1.4M from Breakthrough T1D to Develop Universal Immune-Cloaked Cell Line for Type 1 Diabetes Therapies

6 days ago

Pluristyx announced a $1.4 million collaboration with Breakthrough T1D to create genetically engineered induced pluripotent stem cells for type 1 diabetes islet replacement therapies.

Scientists Engineer Human Stomach Cells to Produce Insulin for Type 1 Diabetes Treatment

14 days ago

Researchers successfully engineered human stomach organoids to produce insulin-secreting cells that resemble pancreatic beta cells when transplanted into mice.

Finerenone Shows Promise as First New Type 1 Diabetes Kidney Treatment in 30 Years

17 days ago

A Phase 3 clinical trial demonstrated that finerenone (Kerendia) reduced protein loss in urine by approximately 25% in 242 type 1 diabetes patients with chronic kidney disease over six months.

Avant Technologies and SGAustria Launch Joint Venture to Develop Stem Cell-Based Diabetes Therapy

18 days ago

Avant Technologies and SGAustria have formed a joint venture called Insulinova to develop diabetes therapies using stem cell and encapsulation technologies targeting type 1 and insulin-dependent type 2 diabetes.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access